SCTX — Scribe Therapeutics Inc.

Is SCTX overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Strong Oversold As of November 17, 2026

Scribe Therapeutics Inc. (SCTX) currently reads Strong Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $15.37. The rating moved from Oversold to Strong Oversold on November 17, 2026.

See all oversold Healthcare stocks →

AI analysis

Scribe Therapeutics Inc. is positioned as an early-stage gene-editing company with meaningful upside tied to clinical progress, partnerships, or M&A interest. Near-term market conditions are cautious and favor large-cap, defensive healthcare names, which may limit momentum for small-cap biotech shares. Key drivers to monitor are clinical readouts, partnership announcements, and financing events; conversely, trial setbacks, regulatory hurdles, and dilution are primary downside catalysts. Given limited public financial disclosure and social sentiment data, expect elevated volatility and sensitivity to news flow in the coming weeks.

Key factors

  • Early-stage gene-editing platform with potential long-term upside if lead programs show clinical progress or attract partnerships
  • Biotech sector risk-off in the short window and flows favoring large-cap, defensive pharma could limit near-term upside
  • Potential acquirer/partner interest among large pharma seeking proprietary gene-editing capabilities
  • Funding and cash runway visibility will materially drive near-term valuation and dilution risk
  • Regulatory environment for novel gene-editing therapeutics remains complex and can affect development timelines
  • Limited publicly available financial and social sentiment data increases uncertainty around market perception

Risks

  • Clinical trial failure or disappointing data for lead programs
  • Need for additional capital leading to dilution or restrictive financing terms
  • Intense competition from other CRISPR/gene‑editing companies and established biotech/pharma R&D
  • Regulatory setbacks or slower-than-expected approval pathways for gene-editing therapeutics
  • Macro risk: risk-off market conditions and defensive sector flows reducing appetite for small-cap biotech
  • Limited liquidity and potentially wide intraday volatility in the share price

See today's live rating, score and targets

Members see the live hourly rating for SCTX — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.